安罗替尼辅助治疗晚期非小细胞肺癌疗效观察  

Anlotinib in adjuvant treatment of patients with advanced non-small cell lung cancer

作　　者：李露[1] 曹卓[1] 潘炯伟[1] 钱俊峰[1] 李雨玲 LI Lu;CAO Zhuo;PAN Jiongwei;QIAN Junfeng;LI Yuling(Department of Respiratory Medicine,Lishui People's Hospital,Lishui 323000,China)

机构地区：[1]丽水市人民医院呼吸内科,323000

出　　处：《浙江医学》2022年第12期1273-1275,1280,共4页Zhejiang Medical Journal

基　　金：北京医卫健康公益基金会医学科学研究基金资助项目(F2033G)。

摘　　要：目的观察安罗替尼辅助治疗晚期非小细胞肺癌(NSCLC)的疗效。方法选取丽水市人民医院2018年1月—2020年1月收治的晚期NSCLC患者123例为研究对象,其中采取安罗替尼联合培美曲塞/紫杉醇+卡铂方案治疗63例,为观察组;仅培美曲塞/紫杉醇+卡铂方案治疗60例,为对照组。以21 d为1个周期,治疗2个周期后观察并比较两组患者近期疗效、生存质量、毒副反应、血清亲环蛋白A(CypA)水平变化等指标。结果观察组患者客观缓解率、生存质量提高率均明显高于对照组(均P<0.05);两组患者骨髓抑制、肝肾功能异常、肝肾功能异常、乏力等不良反应发生率比较,差异均无统计学意义(均P>0.05)。治疗前,两组患者血清CypA水平比较,差异无统计学意义(P>0.05);治疗后,两组患者血清CypA水平均明显降低(均P<0.05),且观察组明显低于对照组(P<0.05)。结论化疗联合安罗替尼辅助治疗晚期NSCLC患者的近期疗效明显,可提高患者生存质量、降低血清CypA水平,且不增加不良反应。Objective To observe the efficacy of anlotinib in adjuvant treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 123 patients with advanced NSCLC admitted to Lishui People's Hospital from January 2018 to January 2020 were enrolled.Sixty three cases were treated with anlotinib plus pemetrexed/paclitaxel+carboplatin regimen(study group),and 60 cases were treated with pemetrexed/paclitaxel+carboplatin regimen alone(control group).Taking 21 days as a cycle,after 2 cycles of treatment,the short-term efficacy,quality of life,toxic and side effects,and changes in serum cyclophilin A(CypA)levels were compared between the two groups.Results The objective remission rate and the improvement rate of quality of life in study group were significantly higher than control group(both P<0.05).There was no significant difference in the incidence of toxic and side effects such as bone marrow suppression,abnormal liver and kidney function,and fatigue between the two groups(all P>0.05).Before treatment,there was no significant difference in serum CypA levels between the two groups(P>0.05);after treatment,the serum CypA levels in both groups were significantly decreased(all P<0.05),while the CypA level in study group was significantly lower than that in control group(P<0.05).Conclusion Anlotinib can enhance the short-term efficacy of chemotherapy for advanced NSCLC patients;and can improve the quality of life of patients and reduce the serum CypA level without increasing the toxic and side effects.

关 键 词：亲环蛋白A 非小细胞肺癌 安罗替尼 疗效 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]